FRANKFURT (dpa-AFX Broker) - Investment bank Oddo BHF has given Evotec an "outperform" rating and a price target of 23 euros. The current low valuation ignores the drug discovery company's strong, data-based technology platforms, analyst Stephan Wulf wrote in a research note issued Tuesday. Evotec is well positioned to benefit from megatrends in healthcare, he added./edh/tih
Publication of the original study: 09.01.2023 / 17:29 / CET.
First disclosure of the original study: 09.01.2023 / 17:37 / CET
-----------------------
dpa-AFX Broker - the Trader News from dpa-AFX
-----------------------